Case Study
Innovator in surgical orthopedic oncology solutions, including limb salvage implants and personalized 3D surgical planning.
Year of Investment
2015
Deal Type
Carveout
Status
Active
Vertical
Pharma/Medtech Products
Location
Parsippany, NJ
Massive Market
Underserved complex orthopedic market (~$2.9B TAM) with beachhead in orthopedic oncology where there is a concentrated physician base.
Innovation Gap
Demand for innovation in precision orthopedics and oncology-focused implants.
Strong Economics
Demand for innovation in precision orthopedics and oncology-focused implants.
Proactive Thesis
Mined and evaluated product universe within orthopedic oncology.
Company Formation
Negotiated carve-out opportunity and co-founded company; actively syndicated equity / debt.
Team Mentorship
Operating Team Members provide commercial, regulatory, and R&D guidance.
1315 Capital’s investment and early strategic involvement were critical to the founding of Onkos Surgical. We successfully carved out assets from a strategic as part of a shared vision of addressing an underserved market in musculoskeletal oncology and complex orthopedics. This approach not only accelerated our entry into the market but also created meaningful long-term value for patients, providers, and investors.
45%
Revenue CAGR Since Inception
99.999%+
Bacteria Kill Rate for NanoCept Technology
10th
De Novo Approval for Orthopedic Implant in FDA history for NanoCept
6,200+
Limbs Saved Since Inception
Key Highlights
Results
Onkos Surgical started with a small product set and a vision to become one of the global leaders in orthopedic oncology. Through the Company’s commercial execution and strategic innovation engine, Onkos has built an industry leading portfolio of state of the art implants that save the limbs and lives of patients.